SCHEDULE 13G/A: Sumitomo Mitsui Trust Group and Nikko Asset Management Disclose 5% Stake in 10x Genomics

Japanese financial giants Sumitomo Mitsui Trust Group and Nikko Asset Management Co., Ltd. have jointly disclosed a significant 5% beneficial ownership stake in biotechnology company 10x Genomics, Inc.

Summary

• Sumitomo Mitsui Trust Group, Inc. and Nikko Asset Management Co., Ltd., both Japanese financial institutions, have filed an Amendment No. 1 to Schedule 13G, disclosing their beneficial ownership in 10x Genomics, Inc.
• As of March 31, 2025, Sumitomo Mitsui Trust Group, Inc. beneficially owns 5,363,366 shares of 10x Genomics' Class A common stock, representing 5.0% of the class.
• Nikko Asset Management Co., Ltd. beneficially owns 5,362,656 shares of 10x Genomics' Class A common stock, also representing 5.0% of the class.
• Both entities report shared voting power and shared dispositive power over their respective holdings.
• The securities are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing the control of 10x Genomics, Inc.
• The beneficial ownership is primarily held through their subsidiaries, including Nikko Asset Management Americas, Inc. and Sumitomo Mitsui Trust Asset Management Co., Ltd.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in tone. The act of institutional investment can be seen as positive, but the document itself does not convey explicit sentiment.

Positives

• The disclosure of a 5% beneficial ownership by major institutional investors like Sumitomo Mitsui Trust Group and Nikko Asset Management Co., Ltd. can signal confidence in 10x Genomics, Inc.'s long-term prospects.
• Increased institutional ownership can enhance the company's visibility and potentially attract further investment.

Risks

• The filing itself does not detail specific risks related to 10x Genomics' operations or financial performance, as it is a beneficial ownership report.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding 10x Genomics, Inc.'s future performance or strategic outlook.

Industry Context

Schedule 13G filings are mandatory disclosures by institutional investors who acquire more than 5% of a company's voting stock, indicating a passive investment intent. This filing reflects a significant stake taken by two prominent Japanese financial groups in a U.S. biotechnology company, which is a common occurrence in global capital markets as institutions diversify their portfolios.

Stakeholder Impact

• Shareholders: The disclosure of significant institutional ownership by reputable financial groups may be viewed positively, potentially increasing investor confidence and market liquidity for 10x Genomics' stock.

Key Dates

Keywords

10x Genomics, Sumitomo Mitsui Trust Group, Nikko Asset Management, Beneficial Ownership, Schedule 13G, Class A Common Stock, Institutional Investment, Biotechnology